The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Silgard human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) | Merck Sharp Dohme Ltd | Papillomavirus Infections; Uterine Cervical Dysplasia; Condylomata Acuminata; Immunization | 🇪🇺 EU 2006-09-19 | Order → |
| Exjade deferasirox Additional monitoring | Novartis Europharm Limited | beta-Thalassemia; Iron Overload | 🇪🇺 EU 2006-08-28 | Order → |
| Thelin sitaxentan sodium | Pfizer Ltd. | Hypertension, Pulmonary | 🇪🇺 EU 2006-08-10 | Order → |
| ATryn antithrombin alfa Exceptional circumstancesAdditional monitoring | Laboratoire Francais du Fractionnement et des Biotechnologies | Antithrombin III Deficiency | 🇪🇺 EU 2006-07-28 | Order → |
| Competact pioglitazone;metformin | CHEPLAPHARM Arzneimittel GmbH | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2006-07-28 | Order → |
| Intrinsa testosterone | Warner Chilcott UK Ltd. | Sexual Dysfunctions, Psychological | 🇪🇺 EU 2006-07-28 | Order → |
| Livensa testosterone | Warner Chilcott Deutschland GmbH | Sexual Dysfunctions, Psychological | 🇪🇺 EU 2006-07-28 | Order → |
| Savene dexrazoxane | CNX Therapeutics Ireland Limited | Extravasation of Diagnostic and Therapeutic Materials | 🇪🇺 EU 2006-07-27 | Order → |
| Nexavar sorafenib | Bayer AG | Carcinoma, Hepatocellular; Carcinoma, Renal Cell | 🇪🇺 EU 2006-07-19 | Order → |
| Sutent sunitinib | Pfizer Limited | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors | 🇪🇺 EU 2006-07-19 | Order → |
| Avaglim rosiglitazone;glimepiride | SmithKline Beecham Ltd | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2006-06-27 | Order → |
| Tysabri natalizumab | Biogen Netherlands B.V. | Multiple Sclerosis | 🇪🇺 EU 2006-06-27 | Order → |
| Baraclude entecavir | Bristol-Myers Squibb Pharma EEIG | Hepatitis B, Chronic | 🇪🇺 EU 2006-06-26 | Order → |
| RotaTeq rotavirus vaccine, live | Merck Sharp & Dohme B.V. | Immunization; Rotavirus Infections | 🇪🇺 EU 2006-06-26 | Order → |
| Acomplia rimonabant | sanofi-aventis | Obesity | 🇪🇺 EU 2006-06-19 | Order → |
| Zimulti rimonabant | sanofi-aventis | Obesity | 🇪🇺 EU 2006-06-19 | Order → |
| Evoltra clofarabine Exceptional circumstancesAdditional monitoring | Sanofi B.V. | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2006-05-29 | Order → |
| Ganfort bimatoprost;timolol | AbbVie Deutschland GmbH & Co. KG | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2006-05-19 | Order → |
| Zostavax shingles (herpes zoster) vaccine (live) | Merck Sharp & Dohme B.V. | Herpes Zoster; Immunization | 🇪🇺 EU 2006-05-19 | Order → |
| M-M-RVaxPro measles, mumps and rubella vaccine (live) | Merck Sharp & Dohme B.V. | Rubella; Mumps; Immunization; Measles | 🇪🇺 EU 2006-05-05 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.